Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple myeloma and patients with bone metastases fro...

Full description

Bibliographic Details
Main Authors: Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:Journal of Bone Oncology
Subjects:
Denosumab
Bone metastasis
Skeletal-related events
Efficacy
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137422000069

Internet

http://www.sciencedirect.com/science/article/pii/S2212137422000069

Similar Items